Delivering improved management and outcomes in diabetic kidney disease in routine clinical care

Abstract

Aim

To examine the impact of service re-design on management and outcomes in type 2 diabetic patients with microalbuminuria and diabetic nephropathy.

Methods

The impact of implementation of evidence-based processes of care (blood pressure [BP] control, glycaemic control, renin-angiotensin-aldosterone system blockade, aspirin and cholesterol-lowering therapy, and smoking cessation) on progression to nephropathy in 338 microalbuminuria patients; and on death, doubling of serum creatinine, new end-stage renal failure (ESRF) and cardiovascular events in 127 nephropathy patients is described.

Results

Effective implementation of evidence-based processes of care improved surrogate outcomes (BP, HbA_1C and low density lipoprotein-cholesterol), was associated with little progression of microalbuminuria to nephropathy (6.1 per 100-patient-years), and in diabetic nephropathy patients were associated with rates of doubling of serum creatinine (1.4 per 100-patient-years), progression to ESRF (1.1 per 100-patient-years), cardiovascular events (3.2 per 100-patient-years) and mortality (2.2 per 100-patient-years) that compares favourably with landmark trials.

Conclusion

Service re-design in the management of type 2 diabetic kidney disease can deliver improved care and outcomes comparable with landmark trials in a routine clinical care setting.

Keywords

death diabetes mellitus dialysis doubling of serum creatinine microalbuminuria nephropathy.

Get full access to this article

View all access options for this article.

References

Gross JL , De Azevedo MJ , Silveiro SP , Canani LH , Caramori ML , Zelmanovitz T. Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care 2005;28:164-76.

Wang SL , Head J. , Stevens L. , Fuller JH Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The World Health Organisation Multinational Study of vascular Disease in Diabetes. Diabetes Care 1996;19:305-12.

Diabetes Control and Complications Trial Research Group. The effect of the intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.

UKPDS Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes mellitus . Lancet 1998, 352:837-53.

OhkuboY, Kishikawa H. , Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.

UKPDS Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.

Gaede P. , Vedel P. , Parving H. , Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-22.

Parving HH , Lehnert H. , Brochner-Mortenson B. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.

Lewis EJ , Hunsicker, LG , Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

10.

Brenner BM , Cooper ME , Zeeuw D. , Keane WF Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.

11.

Mogensen CE , Cooper ME Diabetic renal disease: from recent studies to improved clinical practice. Diabet Med 2004;21:4-17.

12.

ADA (American Diabetes Association). Nephropathy in Diabetes (Position Statement). Diabetes Care 2004;27(suppl 1):S79-S83.

13.

National Institute for Clinical Excellence. Management of type 2 diabetes. Renal disease - prevention and early management. Inherited Clinical Guideline F. London, NICE, London: 2005.

14.

Renal Association. Treatment of adults and children with renal failure: Standards/RenalStandards_2002b.pdf standards and audit measures, 3rd Edition, 2002. www.renal.org/

15.

Rigalleau MD , Lasseur C. , Perlemoine C. et al. Estimation of Glomerular Filtration Rate in Diabetic Subjects. Cockcroft Gault or Modification of Diet in Renal Disease study Equation? Diabetes Care 2005 ;28:838-43.

16.

HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. MICRO_HOPE Substudy. Effects of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus . Lancet 2000; 355:253-9.

17.

Parving HH , Andersen AR , Smidt UM , Svendsen PA Early aggressive antihypertensive treatment reduced rate of decline in kidney function in diabetic nephropathy. Lancet 1983 ;1:1175-9.

18.

Rossing P. , Hommel E. , Smidt UM , Parving HH Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment . Diabetologia 1994;37:511-16.

19.

de Zeeuw D. , Remuzzi G. , Parving HH , Keane WF et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-20.

20.

Mogensen CE Microalbuminuria and hypertension with a focus on type 1 and type 2 diabetes. J Intern Med 2003;254:45-66.

21.

Viberti G. , Wheeldon NM Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: blood pressure independent effect. Circulation 2002;106:672-8.